Kemp Dolliver

Stock Analyst at Brookline Capital

(0)
# 5157
Out of 5,352 analysts
24
Total ratings
16.67%
Success rate
-43.72%
Average return
18 Stocks
Name Action PT Current % Upside Ratings Updated
YMAB Y-mAbs Therapeutics
Initiates Coverage On: Buy
17
4.88 248.36% 1 Dec 5, 2024
EYEN Eyenovia
Downgrades: Hold
n/a
n/a n/a 2 Nov 15, 2024
VRCA Verrica Pharmaceutic...
Downgrades: Hold
n/a
n/a n/a 2 Oct 2, 2024
ONCT Oncternal Therapeuti...
Downgrades: Hold
n/a
n/a n/a 3 Sep 12, 2024
IBIO iBio
Initiates Coverage On: Buy
4
0.84 328.57% 1 Jul 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
36
3.05 1080.33% 2 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Mar 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
32
1.84 1606.52% 1 Jan 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
27 13
n/a n/a 1 Dec 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 19, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
100
77.68 28.73% 1 Nov 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
57
1.99 2764.32% 2 Oct 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
5
n/a n/a 1 Sep 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Hold
25
2.56 876.56% 1 May 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 May 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
19
5.16 263.37% 1 Jan 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
8
0.89 798.88% 1 Oct 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.03 448.54% 1 Feb 2, 2022